Publications

Detailed Information

Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia

DC Field Value Language
dc.contributor.authorChu, Kon-
dc.contributor.authorLee, Soon-Tae-
dc.contributor.authorKoo, Ja-Seong-
dc.contributor.authorJung, Keun-Hwa-
dc.contributor.authorKim, Eun-Hee-
dc.contributor.authorSinn, Dong-In-
dc.contributor.authorKim, Jeong-Min-
dc.contributor.authorKo, Song-Yi-
dc.contributor.authorKim, Se-Jeong-
dc.contributor.authorSong, Eun-Chol-
dc.contributor.authorKim, Manho-
dc.contributor.authorRoh, Jae-Kyu-
dc.date.accessioned2009-11-04T05:10:50Z-
dc.date.available2009-11-04T05:10:50Z-
dc.date.issued2006-
dc.identifier.citationBrain Res. 1093, 208-218en
dc.identifier.issn0006-8993 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16696956-
dc.identifier.urihttps://hdl.handle.net/10371/11105-
dc.description.abstractPeroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, rosiglitazone, not only improves insulin resistance in patients with type II diabetes but also exerts a broad spectrum protective effects in variable animal models of neurologic or cardiovascular diseases. We studied the effect of rosiglitazone on angiogenesis and neurological recovery after focal cerebral ischemia. Rosiglitazone (3 mg/kg or 0.3 mg/kg, p.o.) was administered for 7 days prior to and 3 days after the induction of focal ischemia (total 10 days) in adult rats. The rosiglitazone-treated group showed the enhanced neurologic improvement, the reduced infarction volume compared to the ischemia-vehicle group with dose dependency, and the reduced hemispheric atrophy. Rosiglitazone treatment reduced TUNEL(+)/activated caspase-3(+) cells, MPO(+)/Ox-42(+) inflammatory cell infiltrations, caspase-3 activity, and Bax(+) cells, as compared to the ischemia-vehicle group. The vascular surface area, the vascular branch points, the vascular length, and the number of BrdU(+) endothelial cells were significantly increased in the rosiglitazone group compared with the ischemia-vehicle group. Rosiglitazone increased eNOS expression around the ischemic margin with downregulation of FasL. Here, we show that rosiglitazone treatment enhances angiogenesis and functional recovery with dose-dependent induction of ischemic tolerance.en
dc.description.sponsorshipThis study was supported by the Ministry of Health and
Welfare (A050230), Republic of Korea
en
dc.language.isoen-
dc.publisherElsevieren
dc.subjectPeroxisome proliferator-activateden
dc.subjectreceptor-γ-agonisten
dc.subjectRosiglitazoneen
dc.subjectCerebral ischemiaen
dc.subjectAngiogenesisen
dc.subjectIschemic toleranceen
dc.subjecteNOSen
dc.titlePeroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemiaen
dc.typeArticleen
dc.contributor.AlternativeAuthor주건-
dc.contributor.AlternativeAuthor이순태-
dc.contributor.AlternativeAuthor구자성-
dc.contributor.AlternativeAuthor정근화-
dc.contributor.AlternativeAuthor김은희-
dc.contributor.AlternativeAuthor신동인-
dc.contributor.AlternativeAuthor김정민-
dc.contributor.AlternativeAuthor고송이-
dc.contributor.AlternativeAuthor송은철-
dc.contributor.AlternativeAuthor김세정-
dc.contributor.AlternativeAuthor김만호-
dc.contributor.AlternativeAuthor노재규-
dc.identifier.doi10.1016/j.brainres.2006.03.114-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share